Lathosterol and other Noncholesterol Sterols in Treatment of Hereditary Hypercholesterolemias: 20-Year Experience among School Children and Adolescents

Authors

  • Josef Hyánek Metabolic Centre, Hematology and Immunology; both Na Homolce Hospital, Prague, (Nemocnice Na Homolce, Roentgenova 2, 150 30 Praha 5), Czech Republic
  • František Pehal Department of Clinical Biochemistry, Hematology and Immunology; both Na Homolce Hospital, Prague, (Nemocnice Na Homolce, Roentgenova 2, 150 30 Praha 5), Czech Republic
  • Ladislava Dubská Department of Clinical Biochemistry, Hematology and Immunology; both Na Homolce Hospital, Prague, (Nemocnice Na Homolce, Roentgenova 2, 150 30 Praha 5), Czech Republic
  • Blanka Miková Department of Clinical Biochemistry, Hematology and Immunology; both Na Homolce Hospital, Prague, (Nemocnice Na Homolce, Roentgenova 2, 150 30 Praha 5), Czech Republic
  • Vera Martiníková Metabolic Centre, Hematology and Immunology; both Na Homolce Hospital, Prague, (Nemocnice Na Homolce, Roentgenova 2, 150 30 Praha 5), Czech Republic
  • Jana Privarová Metabolic Centre, Hematology and Immunology; both Na Homolce Hospital, Prague, (Nemocnice Na Homolce, Roentgenova 2, 150 30 Praha 5), Czech Republic
  • Jana Brtnová Department of Clinical Biochemistry, Hematology and Immunology; both Na Homolce Hospital, Prague, (Nemocnice Na Homolce, Roentgenova 2, 150 30 Praha 5), Czech Republic
  • Ludek Táborský Department of Clinical Biochemistry, Hematology and Immunology; both Na Homolce Hospital, Prague, (Nemocnice Na Homolce, Roentgenova 2, 150 30 Praha 5), Czech Republic

DOI:

https://doi.org/10.6000/1929-5634.2018.07.02.2

Keywords:

Noncholesterol sterols, lathosterol, desmosterol, campesterol, sitosterol, phytosterols, heterozygous familial hypercholesterolemia, alimentary hyperlipidemia, monitoring diet and drug treatment, simvastatins, ezetimibe.

Abstract

Aims: This paper presents our 20-year experience with diagnosing heterozygous familial hypercholesterolemia (HFH) and monitoring its diet and drug treatment in 94 children (6-18 years) by means of noncholesterol sterols (NCS), namely lathosterol (Lat) and desmosterol (Des) as cholesterol synthesis precursors, and campesterol (Cam) and sitosterol (Sit) as cholesterol absorption precursors.

Patients and Methods: Four groups were included in the study: (1) 64 children with genetically confirmed HFH; (2) 30 children with clinical and laboratory symptoms of HFH where the relevant genetic mutations have not been found; (3) 77 children with alimentary hyperlipidemia (AH), and (4) 84 healthy children as a control group. The followed-up markers were routine lipid profile comprising total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triacylglycerides (TAG), complemented by apolipoprotein A1 (ApoA), apolipoprotein B (ApoB), lipoprotein(a) (Lp(a)), low-density lipoprotein receptor (LDL-R), apolipoprotein E (ApoE) polymorphism, and plasma NCS (Lat, Des, Cam and Sit), the latter being established by means of GC/MS. The medical treatment of HFH patients consisted of simvastatin and ezetimibe. Correlations between TC lowering and decrease in Lat and other NCS values during combination treatment were examined in various types of hypercholesterolemia.

Results: HFH patients, whether genetically confirmed or not, exhibit a significant decrease in Lat (and in milder concentrations also Des) which correlates directly to the TC lowering during the combination therapy (r = 0.912 for Lat;
r = 0.798 for Des; p<0.001). Cam and Sit do not correlate with the TC lowering at all (r = -0.378 for Cam; r = -0.208 for Sit). By contrast, high TC levels in AH patients are not accompanied by significantly elevated Lat levels, and, therefore, caloric restriction cannot result in significant Lat or Des decrease (p<0.001). Lat and Des levels are also high following drug treatment interruption during long vacations or when the drug treatment is neglected. Compensatory elevation of Cam and Sit occurs in 50% of treated children patients after the desirable TC level below 4.8 mmol/l has been achieved and maintained. In our experience, the combination of statin and ezetimibe is the most efficacious therapy to lower TC together with Lat and Des in children with HFH.

Conclusions: Inclusion precursors for cholesterol synthesis and absorption in laboratory testing improve differential diagnosis of HFH, and makes monitoring and/or treatment of pediatric patients more precise and convenient.

References

Avis HJ, Hutten BA, Gagné V, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010; 55: 1121-26. https://doi.org/10.1016/j.jacc.2009.10.042

Wiegman A, Hutten BA, deGroot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292: 331-337. https://doi.org/10.1001/jama.292.3.331

deJongh S, Ose L, Szamosi T, Gagne C, Lambert M, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo controlled trial with simvastatin. Circulation 2002; 106: 2231-37. https://doi.org/10.1161/01.CIR.0000035247.42888.82

Gauer R. Hyperlipidemia treatment in children:The younger, the better. Am Family Physician 2010; 82: 462-477.

Bogsrud MP, Langslet G, Wium C, et al. Treatment goal attainment in children with familial hypercholesterolemia:a cohort study of 302 children in Norway. J Clin Lipidol 2017.

https://doi.org.10.1016/j.jact2017.11.009

Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Pediatrics, 2011, S 213-S256.

Noto D, Cefalu ABC, Barraco G, et al. Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia. Pediatr Res 2010; 67: 200-204. https://doi.org/10.1203/PDR.0b013e3181c8f035

Hedman M, Miettinen TA, Gylling H, Ketomäki A, Antikainen M. Serum noncholesterol sterols in children with hetero-zygous familial hypercholesterolemia undergoing pravastatin therapy. J Pediat 2006; 148: 241-246. https://doi.org/10.1016/j.jpeds.2005.08.068

Nissien MJ, Miettinen TE, Gylling H, Miettinen TA. Applicability of noncholesterol sterols in predicting response in cholesterol metabolism to simvastatin and fluvastatin treatment among hypercholesterolemic men. Nutr Metab Cardiovasc Dis 2010; 20: 308-316. https://doi.org/10.1016/j.numecd.2009.04.014

Rodenburg J, Wissers MN, Wiegmasn A, et al. Statin treatmen tin children with familial hypercholesterolemia: a ranadomized controlled trial. JAMA 2004; 292: 331-37. https://doi.org/10.1001/jama.292.3.331

McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a specific statement from the American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115: 1948-67. https://doi.org/10.1161/CIRCULATIONAHA.107.181946

Hyanek J, Martinikova V, Matoska V, et al. 10years experience with medical treatment of familial hypercholesterolemia in children and adolescents. Česko-slov. pediatrie 2006; 61: 404-412, (in Czech with English summary).

NCEP Expert panel of blood cholesterol levels in children and adolescents.National Cholesterol Education Program(NCEP):Highlights of the Report of the Expert Panel on Pediatrics 1992; 89: 495-501.

Rifkind BM, Segal P. Lipid research clinic program reference values for hyperlipidemia and hypolipidemia. JAMA 1983; 250: 1869-1872. https://doi.org/10.1001/jama.1983.03340140039025

Clauss S, Wai KM, Kavey RW, Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediat 2009; 154: 869-872. https://doi.org/10.1016/j.jpeds.2008.12.044

Hyanek J, Pehal F, Dubska L, et al. Lathosterol and noncholesterol sterols in routine use for the differentiation andmonitoring of dietary and drug induced treatment of hypercholesterolemias in children and adolescents. JNT 2014; 3: 1-12.

Hyanek J. Serum non-cholesterol sterols in differentiation and treatment of children suffering from hypercholesterolemias; Chapter VI. In Phytosterols-Food Sources, Functions and Health Benefits (Ed. D. Garner), Progress in Food Science and Technology. NOVA´s website 2015; pp. 97-116.

Francova H, Trbusek M, Zapletalova P, et al. New promoter mutations in the low-density lipoprotein receptor gene which induced familialhypercholesterolemia phenotype. Molecular and functional analysis. J Inher Metab Dis 2004; 27: 523-28. https://doi.org/10.1023/B:BOLI.0000037337.93335.c4

Tichy L, Fajkusova L, Zapletalova P, et al. Molecular genetic backgraund on an autosomal dominant hypoercholessterolemia in the Czech Republic Physiol Res 2017; 66(Suppl.1): S47-54.

Tichy L, Freiberg T, Zapletalov P, et al. The molecular basis offamilial cholesterolemia in Czech Republic: spetrum of LDLR mutations and genotype-phenotype corrrelations. Atherosclerosis 2012; 223: 401-8. https://doi.org/10.1016/j.atherosclerosis.2012.05.014

Phillips KM, Ruggio DM, Bailey JA. Precise quantitative determination of phytosterols, stenols, and cholesterol metabolites in human serum, by capillary gas-liquid chromatography. J Chromatog 1999; B732: 17-29.

Theunissen CE, Regente J, Bergman K, et al. Serum cholesterol precursors and metabolites and cognitive performace in an aging population. Neurobiol Aging 2003; 24: 147-155. https://doi.org/10.1016/S0197-4580(02)00061-1

Hyanek J, Dubska L, Martinikova V, et al. The influence of menarche on high cholesterol level in adolescent girls with familial hypercholesterolemia. Čs Slov Pediat 2013; 68: 12-18. (in Czech with English summary).

MacKay DS, Jones PJH. Plasma noncholesterol sterols:corrent uses potential and need for standardization. Curr Opin Lipidol 2012; 23: 241-47. https://doi.org/10.1097/MOL.0b013e328353292e

MacKay DS, Jones PJH. Evaluation of methods for the determination of cholesterol absorption and synthesis in humans. Atherosclerosis 2001; 218: 253-62. https://doi.org/10.1016/j.atherosclerosis.2010.04.022

Sutherland WHF, Williamns MJA, Nye NJ, Restieaux NJ, deJong SA, Walker HL. Associations of plasma noncholesterol sterol levels with severity of coronary artery disease. Nutr Metab Cardiovasc Dis 1998; 8: 389-391.

Sudhop T, Reber M, Tribble D, et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res 2009; 50: 2117-2123. https://doi.org/10.1194/jlr.P900004-JLR200

Lupatelli G, Pirro M, Siepi D, et al. Non-cholesterol sterols in different forms of primary hyperlipemias. Nutr Metab Cardiovasc Dis 2012; 22: 231-6. https://doi.org/10.1016/j.numecd.2010.05.010

Miettinen TA, Gylling H, Nissinen MJ. The role of serum non-cholesterol sterols as surrogate markers of absolute cholesterol synthesis and absorption. Nutr Metab Cardiovasc Dis 2011; 21: 765-769. https://doi.org/10.1016/j.numecd.2011.05.005

Downloads

Published

2018-08-15

How to Cite

Hyánek, J., Pehal, F., Dubská, L., Miková, B., Martiníková, V., Privarová, J., Brtnová, J., & Táborský, L. (2018). Lathosterol and other Noncholesterol Sterols in Treatment of Hereditary Hypercholesterolemias: 20-Year Experience among School Children and Adolescents. Journal of Nutritional Therapeutics, 7(2), 40–50. https://doi.org/10.6000/1929-5634.2018.07.02.2

Issue

Section

Articles